Beximco Pharma Enters EU Market  

Beximco Pharmaceuticals Limited (BPL), a fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients has started exporting products to Europe.

Initially shipments of two ophthalmic products, Latanoprost and a combination of Latanoprost and Timolol, will be exported to Germany and Austria with other EU countries to follow. These medications are used to reduce the pressure inside the eye for people with open-angle glaucoma or intraocular hypertension (increased pressure in the eye). The Company expects to launch additional new products in the EU later this year.

Managing Director of Beximco Pharma, Nazmul Hassan MP, commented:
“Beximco has established a presence in a growing number of markets around the world. The Company is increasingly focused on penetrating large and highly regulated markets such as the EU and US, where the demand for generic products continues to rise. Beximco has developed high quality pharmaceutical facilities in Bangladesh, with a competitive cost structure for manufacturing and exporting generic drugs. This is a combination that is of increasing importance as governments strive to reduce healthcare costs without compromising on quality. We look forward to launching further products in Europe, the 2nd largest pharmaceutical market in the world with sales in excess of US$265 billion1, and providing patients with safe and affordable treatment options."